Molecular Response to Nilotinib in a Patient with Imatinib-intolerant e19a2-positive Chronic Myeloid Leukemia
-
- Kajiguchi Tomohiro
- Department of Hematology and Oncology, Tosei General Hospital, Japan
-
- Okuno Shingo
- Department of Hematology and Oncology, Tosei General Hospital, Japan
-
- Ohno Toshihito
- Department of Hematology and Oncology, Tosei General Hospital, Japan
-
- Abe Akihiro
- Department of Hematology, Fujita Health University School of Medicine, Japan
Search this article
Abstract
The BCR-ABL1 fusion gene is the molecular marker of chronic myeloid leukemia (CML). The e19a2 transcript is a rare variant associated with various clinical presentations and courses of CML. We herein present a case of e19a2-positive CML who was intolerant to initial treatment with imatinib and successfully responded to subsequent nilotinib therapy. She achieved a major molecular response and has since be able to sustain it. According to the literature, achieved molecular response by imatinib monotherapy has not yet been reported in e19a2-positive CML patients. Second generation tyrosine kinase inhibitors may therefore be a more effective treatment for e19a2-positive CML patients.<br>
Journal
-
- Internal Medicine
-
Internal Medicine 53 (24), 2801-2804, 2014
The Japanese Society of Internal Medicine
